nice!_老虎社区_美港股上老虎

yolopororo
2021-07-16

nice!

Drugmaker GSK plans $550 mln expansion of England R&D facility

July 16 (Reuters) - Britain's GlaxoSmithKline on Friday laid out plans to set up a new life sciences

Drugmaker GSK plans $550 mln expansion of England R&D facility

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":170828277,"tweetId":"170828277","gmtCreate":1626421555899,"gmtModify":1633926892535,"author":{"id":4088951070418820,"authorId":4088951070418820,"authorIdStr":"4088951070418820","name":"yolopororo","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":0,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>nice!</p></body></html>","htmlText":"<html><head></head><body><p>nice!</p></body></html>","text":"nice!","highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/170828277","repostId":2151508331,"repostType":4,"repost":{"id":"2151508331","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1626420022,"share":"https://www.laohu8.com/m/news/2151508331?lang=&edition=full","pubTime":"2021-07-16 15:20","market":"us","language":"en","title":"Drugmaker GSK plans $550 mln expansion of England R&D facility","url":"https://stock-news.laohu8.com/highlight/detail?id=2151508331","media":"Reuters","summary":"July 16 (Reuters) - Britain's GlaxoSmithKline on Friday laid out plans to set up a new life sciences","content":"<p>July 16 (Reuters) - Britain's GlaxoSmithKline&nbsp;on Friday laid out plans to set up a new life sciences campus within its R&amp;D site in Stevenage, England, raising up to 400 million pounds ($552.76 million) by selling some land at the facility.</p>\n<p>The London-listed drugmaker said it expects to select a private-sector developer later this year and sell 33 acres of the 92-acre site. Work on the project, backed by the UK government, is expected to begin in 2022.</p>\n<p>GSK, locking horns with activist investor Elliott, is preparing for a planned spin-off of its consumer healthcare venture and focus on its prescription drugs and vaccines business, with heavy investments to develop a new line of products.</p>\n<p>\"Our goal is for Stevenage to emerge as the top destination for medical and scientific research by the end of the decade,\" said GSK senior executive Tony Wood.</p>\n<p>GSK hopes to create up to 5,000 jobs in the next five to 10 years with the addition of the new campus.</p>\n<p>Stevenage is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of GSK's two global R&amp;D hubs and houses the UK's largest cell and gene therapy cluster.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Drugmaker GSK plans $550 mln expansion of England R&D facility</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDrugmaker GSK plans $550 mln expansion of England R&D facility\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-07-16 15:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>July 16 (Reuters) - Britain's GlaxoSmithKline&nbsp;on Friday laid out plans to set up a new life sciences campus within its R&amp;D site in Stevenage, England, raising up to 400 million pounds ($552.76 million) by selling some land at the facility.</p>\n<p>The London-listed drugmaker said it expects to select a private-sector developer later this year and sell 33 acres of the 92-acre site. Work on the project, backed by the UK government, is expected to begin in 2022.</p>\n<p>GSK, locking horns with activist investor Elliott, is preparing for a planned spin-off of its consumer healthcare venture and focus on its prescription drugs and vaccines business, with heavy investments to develop a new line of products.</p>\n<p>\"Our goal is for Stevenage to emerge as the top destination for medical and scientific research by the end of the decade,\" said GSK senior executive Tony Wood.</p>\n<p>GSK hopes to create up to 5,000 jobs in the next five to 10 years with the addition of the new campus.</p>\n<p>Stevenage is <a href=\"https://laohu8.com/S/AONE.U\">one</a> of GSK's two global R&amp;D hubs and houses the UK's largest cell and gene therapy cluster.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GSK":"葛兰素史克"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2151508331","content_text":"July 16 (Reuters) - Britain's GlaxoSmithKline on Friday laid out plans to set up a new life sciences campus within its R&D site in Stevenage, England, raising up to 400 million pounds ($552.76 million) by selling some land at the facility.\nThe London-listed drugmaker said it expects to select a private-sector developer later this year and sell 33 acres of the 92-acre site. Work on the project, backed by the UK government, is expected to begin in 2022.\nGSK, locking horns with activist investor Elliott, is preparing for a planned spin-off of its consumer healthcare venture and focus on its prescription drugs and vaccines business, with heavy investments to develop a new line of products.\n\"Our goal is for Stevenage to emerge as the top destination for medical and scientific research by the end of the decade,\" said GSK senior executive Tony Wood.\nGSK hopes to create up to 5,000 jobs in the next five to 10 years with the addition of the new campus.\nStevenage is one of GSK's two global R&D hubs and houses the UK's largest cell and gene therapy cluster.","news_type":1},"isVote":1,"tweetType":1,"viewCount":25,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":5,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}